In Europe, Mr. Speaker, it is compulsory for negotiators of the Canada-EU trade agreement to keep parliament informed and obtain consent on all stages of negotiations. Yet here all we get is secrecy from the government.
The current position would have Canada adopt EU intellectual property standards, forcing higher drug costs on Canadians, $2.8 billion in fact. Last fall, the negotiator admitted that there was no critical internal analysis done. What is the minister's specific position on the costs of drugs as it relates to the agreement—